SPEVIGO CHMP positive opinion new indications
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
Search
Purevax range now available in 0.5 ml presentation
Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
commitments to sustainable development
On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
International Women’s Day: gender and health equity
On International Women’s Day, we join forces to collectively strive for gender and health equity, empowering women in and beyond our company.
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
FOYA_Shanghai
Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
CARMELINA-elderly-analysis
CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
Embracing diversity in clinical trials
At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
The generalized pustular psoriasis (GPP) Forum 2023
An executive summary of the activities and key takeaways from the GPP Forum 2023
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
World Rabies Day 2020 sustainable dog vaccination
World Rabies Day 2020 sustainable dog vaccination
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
European Commission grants marketing authorization for spesolimab, the first specific treatment option for generalized pustular psoriasis flares in adults
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).